Clinical evaluation of the effectiveness of a topical product prepared from cotton in stopping bleeding from the site of leech therapy
- Conditions
- Bleeding from the site of leech therapy.Coagulation defect, unspecifiez, Haemorrhagic condition, unspecifiedD69.9
- Registration Number
- IRCT20220625055267N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Adults who have leech therapy indication according to the doctor's opinion.
Clinical or laboratory evidence of coagulation disorder (ecchymosis, hematoma, petechiae purpura or disorder in PT, PTT, hemoglobin, platelets, glucose, calcium, urea, creatinine)
Patients who take drugs that affect coagulability, including anti-platelets (aspirin, clopidogrel (Plavix), dipyridamole (Perzantin), ticlopidine (Ticlid), anticoagulants (warfarin, enoxaparin, rivaroxaban, heparin, streptokinase, etc.), blood thinners such as tranexamic acid, vitamin K, aminocaproic acid and statins and oral contraceptives and herbal anticoagulants such as products containing ginger and garlic
??????? ????? ???????? ??????? ????? ??? ITP? ??????? ? ????? ????? ??????? ???? ????
Patients with various malignancies
Menstruating women
Leech therapy in the face area
Skin sensitivity to the product
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of wounds whose bleeding will be completely stopped after local administration of the product. Timepoint: Fifteen minutes after using the product. Method of measurement: Monitoring bleeding from the site by clinical observation.
- Secondary Outcome Measures
Name Time Method Clinical Bleeding from the site of leech therapy after the patient leaves the clinic. Timepoint: After leaving the clinic up to 72 hours after using the product. Method of measurement: Observing bleeding from the wound site.;Possible side effects caused by the administration of the product within 72 hours after the administration of the product. Timepoint: From the time of leaving the clinic until 72 hours later. Method of measurement: Reporting the complication by the patient.